What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Malignant Neoplasm
- Main trialPhase 1/2
- “This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.”In the company’s words, NCT06394713 on ClinicalTrials.gov
Other drugs for Advanced Malignant Neoplasm
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 15 Jun 2025 | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | |
| Phase 2Unknown | Oct 2023 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | |
| Phase 1Unknown | 31 Mar 2024 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026